Chris Nave
Partner, Managing Director & Co-Founder @ Brandon Capital
Melbourne, Australia
Chris Nave is a Series A investor at Brandon Capital in Melbourne focused on Biotechnology and Health Care. Chris Nave is the Co-Founder, Partner, and Managing Director of Brandon Capital Partners. He previously worked at Baker Heart Research Institute as a Directorof Commercialisation. Chris Nave attended the University of Melbourne.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 65%
Last updated:
For AI agents: llms.txt
Industries Chris Nave invests in
Stages Chris Nave invests in
Countries Chris Nave invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (35%)
- Health Care 6 (26%)
- Medical 5 (22%)
- Therapeutics 3 (13%)
- Pharmaceutical 2 (9%)
Stage
- Series A 4 (17%)
- Series B 3 (13%)
- Series C 3 (13%)
- Grant 2 (9%)
- Venture - Series Unknown 2 (9%)
Country
- Australia 5 (22%)
- United Kingdom 2 (9%)
- Israel 1 (4%)
- United States 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M / Series B / Oct 22, 2025 | ||
| PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. | $25.7M / Series C / May 30, 2025 | ||
| Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021. | Grant / Jul 20, 2022 | ||
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $24.2M / Venture - Series Unknown / Jun 17, 2021 | ||
| Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. | $20M / Series C / Oct 22, 2020 | ||
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $8.3M / Series A / Sep 28, 2020 | ||
| Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. | $13.2M / Series A / Dec 18, 2019 | ||
| Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021. | $9.5M / Series A / Sep 25, 2019 | ||
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $30M / Private Equity / Aug 27, 2019 | ||
| Certa Therapeutics is a clinical stage biotechnology company developing innovative therapies for the treatment of fibrotic diseases. | $19.1M / Grant / Jun 04, 2018 | ||
| See all 23 investments → | |||
Co-Investors
About Brandon Capital
Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.
Brandon Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Chris Nave
Partner, Managing Director & Co-Founder
|
|||
Robert Daniels
Venture Partner
|
|||
Stephen Thompson
Partner
|
|||
Bob Soh
Senior Investment Manager
|
|||
Christopher Smith
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris Nave invest in?
Chris Nave invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Nave?
Public channels for Chris Nave include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Nave last invest?
The most recent investment recorded for Chris Nave closed in Oct 2025. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
